Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - hypertension - agents agissant sur le système rénine-angiotensine - traitement de l'hypertension essentielle. copalia est indiqué chez les patients dont la pression artérielle n'est pas adéquatement contrôlée sur l'amlodipine ou le valsartan en monothérapie.

Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunosuppresseurs - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriasique arthritiscosentyx, seul ou en association avec le méthotrexate (mtx), est indiqué pour le traitement des actifs de l'arthrite psoriasique chez les patients adultes lorsque la réponse à la précédente modificateurs de la maladie anti rhumatismale de la drogue (armm) la thérapie a été insuffisante. imagerie de la spondylarthrite axiale (axspa)la spondylarthrite ankylosante, radiographie d'imagerie de la spondylarthrite axiale)cosentyx est indiqué pour le traitement de la spondylarthrite ankylosante active chez les adultes qui ont répondu de manière inadéquate à un traitement classique. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm limited - l'amlodipine, valsartan - hypertension - agents agissant sur le système rénine-angiotensine - traitement de l'hypertension essentielle. dafiro est indiqué chez les patients dont la pression artérielle n'est pas adéquatement contrôlée sur l'amlodipine ou le valsartan en monothérapie.

Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm limited - le travoprost, le timolol - glaucoma, open-angle; ocular hypertension - ophtalmologiques - diminution de la pression intraoculaire (pio) chez les patients adultes atteints de glaucome à angle ouvert ou d'hypertension oculaire insuffisamment sensibles aux bêta-bloquants topiques ou aux analogues de la prostaglandine.

Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - arrêt cardiaque - l'angiotensine ii antagonistes, d'autres combinaisons, les agents agissant sur le système rénine-angiotensine - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm ltd - bromure de glycopyrronium - maladie pulmonaire, chronique obstructive - les médicaments pour les maladies respiratoires obstructives, - enurev breezhaler est indiqué comme traitement bronchodilatateur d'entretien pour soulager les symptômes chez les patients adultes atteints de bronchopneumopathie chronique obstructive (bpco)..

Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm limited - la vildagliptine, la metformine chlorhydrate de - diabète sucré, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - hypertension - agents agissant sur le système rénine-angiotensine - traitement de l'hypertension essentielle. exforge est indiqué chez les patients dont la pression artérielle n'est pas adéquatement contrôlée sur l'amlodipine ou le valsartan en monothérapie.

Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm limited - vildagliptine - diabète sucré, type 2 - les médicaments utilisés dans le diabète - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Europese Unie - Frans - EMA (European Medicines Agency)

novartis europharm limited - maléate d'indacatérol - maladie pulmonaire, chronique obstructive - les médicaments pour les maladies respiratoires obstructives, - hirobriz breezhaler est indiqué pour le traitement bronchodilatateur d'entretien de l'obstruction des voies respiratoires chez les patients adultes atteints de bronchopneumopathie chronique obstructive.